Baseline demographic, clinical, laboratory and tumor staging characteristics of patients
| Characteristic | Value |
|---|---|
| Age, [years] | 67.5 ± 7.8 |
| Gender (M/F), n [%] | 32/3 [91.4/8.6] |
| Cirrhosis (yes/no), n [%] | 30/5 [85.7 /14.3] |
| Etiology of cirrhosis, n [%]: | |
| Ethanol | 13 [43.3] |
| HBV | 4 [13.3] |
| HCV | 4 [13.3] |
| other | 9 [29.9] |
| Albumin [g/l] | 38.4 ± 4.6 |
| INR | 1.2 ± 0.2 |
| Total bilirubin [μmol/l] | 25.6 ± 17.4 |
| Child-Pugh score (points) | 6.0 ± 0.7 |
| Child-Pugh score (classes), n [%]: | |
| A | 22 [73.3] |
| B | 8 [26.7] |
| Creatinine [μmol/l] | 81.7 ± 23.4 |
| ASAT [μkat/l] | 1. 1 ± 0.7 |
| ALAT [μkat/l] | 0.8 ± 0.6 |
| γGT [μkat/l] | 2.3 ± 1.6 |
| αFP [kIE/l] | 152.5 ± 310.2 |
| Portal vein thrombosis (yes/no), n [%] | 6/29 [17.1/82.9] |
| Bilobar disease, n [%] | 11 [31.4] |
| Unilobar disease, n [%:] | 24 [68.6] |
| right lobe, n [%] | 20 [83.3] |
| Overall number of nodules, n | 97 |
| Number of nodules per pt, n | 2.8 ± 2.2 |
| Maximum diameter of HCC nodule per pt. [cm] | 4.7 ± 1.9 |
Number and type of minor complications after DEBDOX TACE_
| Type of complication | No. of complications |
|---|---|
| Post-embolization syndrome * Post-embolization syndrome was defined as elevated body temperature, pain in the abdomen, nausea and/or vomiting, leukocytosis and elevated liver enzymes. | 23 |
| Rise in blood pressure | 4 |
| Gastric erosions or ulcers | 2 |
| Chest pain | 2 |
| Hematoma at puncture site | 1 |